Toll Free: 1-888-928-9744

Hepatitis B - Pipeline Review, H1 2016

Published: May 31, 2016 | Pages: 386 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hepatitis B - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Hepatitis B - Pipeline Review, H1 2016', provides an overview of the Hepatitis B pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Hepatitis B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hepatitis B
- The report reviews pipeline therapeutics for Hepatitis B by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Hepatitis B therapeutics and enlists all their major and minor projects
- The report assesses Hepatitis B therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Hepatitis B


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Hepatitis B
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 7 Hepatitis B Overview 8 Therapeutics Development 9 Hepatitis B - Therapeutics under Development by Companies 11 Hepatitis B - Therapeutics under Investigation by Universities/Institutes 18 Hepatitis B - Pipeline Products Glance 19 Hepatitis B - Products under Development by Companies 23 Hepatitis B - Products under Investigation by Universities/Institutes 32 Hepatitis B - Companies Involved in Therapeutics Development 33 Hepatitis B - Therapeutics Assessment 109 Drug Profiles 121 Hepatitis B - Recent Pipeline Updates 310 Hepatitis B - Dormant Projects 348 Hepatitis B - Discontinued Products 358 Hepatitis B - Product Development Milestones 359 Appendix 368
List of Tables
Number of Products under Development for Hepatitis B, H1 2016 26 Number of Products under Development for Hepatitis B - Comparative Analysis, H1 2016 27 Number of Products under Development by Companies, H1 2016 29 Number of Products under Development by Companies, H1 2016 (Contd..1) 30 Number of Products under Development by Companies, H1 2016 (Contd..2) 31 Number of Products under Development by Companies, H1 2016 (Contd..3) 32 Number of Products under Development by Companies, H1 2016 (Contd..4) 33 Number of Products under Development by Companies, H1 2016 (Contd..5) 34 Number of Products under Investigation by Universities/Institutes, H1 2016 35 Comparative Analysis by Late Stage Development, H1 2016 36 Comparative Analysis by Clinical Stage Development, H1 2016 37 Comparative Analysis by Early Stage Development, H1 2016 38 Comparative Analysis by Unknown Stage Development, H1 2016 39 Products under Development by Companies, H1 2016 40 Products under Development by Companies, H1 2016 (Contd..1) 41 Products under Development by Companies, H1 2016 (Contd..2) 42 Products under Development by Companies, H1 2016 (Contd..3) 43 Products under Development by Companies, H1 2016 (Contd..4) 44 Products under Development by Companies, H1 2016 (Contd..5) 45 Products under Development by Companies, H1 2016 (Contd..6) 46 Products under Development by Companies, H1 2016 (Contd..7) 47 Products under Development by Companies, H1 2016 (Contd..8) 48 Products under Investigation by Universities/Institutes, H1 2016 49 Hepatitis B - Pipeline by Abivax S.A., H1 2016 50 Hepatitis B - Pipeline by AiCuris GmbH & Co. KG, H1 2016 51 Hepatitis B - Pipeline by AIMM Therapeutics B.V., H1 2016 52 Hepatitis B - Pipeline by Akshaya Bio Inc., H1 2016 53 Hepatitis B - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 54 Hepatitis B - Pipeline by AlphaMab Co., Ltd, H1 2016 55 Hepatitis B - Pipeline by Altimmune, Inc., H1 2016 56 Hepatitis B - Pipeline by Altravax, Inc., H1 2016 57 Hepatitis B - Pipeline by Amarna Therapeutics B.V., H1 2016 58 Hepatitis B - Pipeline by Arbutus Biopharma Corporation, H1 2016 59 Hepatitis B - Pipeline by Arrowhead Pharmaceuticals, Inc., H1 2016 60 Hepatitis B - Pipeline by Assembly Biosciences, Inc., H1 2016 61 Hepatitis B - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H1 2016 62 Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 63 Hepatitis B - Pipeline by Benitec Biopharma Limited, H1 2016 64 Hepatitis B - Pipeline by BioDiem Ltd, H1 2016 65 Hepatitis B - Pipeline by Biogenomics Limited, H1 2016 66 Hepatitis B - Pipeline by Biological E. Limited, H1 2016 67 Hepatitis B - Pipeline by BioStar Pharmaceuticals, Inc., H1 2016 68 Hepatitis B - Pipeline by Bolder Biotechnology, Inc., H1 2016 69 Hepatitis B - Pipeline by Bukwang Pharm.Co., Ltd., H1 2016 70 Hepatitis B - Pipeline by CaroGen Corporation, H1 2016 71 Hepatitis B - Pipeline by Celltrion, Inc., H1 2016 72 Hepatitis B - Pipeline by Chimerix, Inc., H1 2016 73 Hepatitis B - Pipeline by ChronTech Pharma AB, H1 2016 74 Hepatitis B - Pipeline by Cocrystal Pharma, Inc., H1 2016 75 Hepatitis B - Pipeline by ContraVir Pharmaceuticals, Inc., H1 2016 76 Hepatitis B - Pipeline by CyTuVax B.V., H1 2016 77 Hepatitis B - Pipeline by Dynavax Technologies Corporation, H1 2016 78 Hepatitis B - Pipeline by Ensemble Therapeutics Corporation, H1 2016 79 Hepatitis B - Pipeline by Enyo Pharma S.A.S., H1 2016 80 Hepatitis B - Pipeline by eTheRNA Immunotherapies NV, H1 2016 81 Hepatitis B - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 82 Hepatitis B - Pipeline by GeneCure LLC, H1 2016 83 Hepatitis B - Pipeline by Gilead Sciences, Inc., H1 2016 84 Hepatitis B - Pipeline by GlaxoSmithKline Plc, H1 2016 85 Hepatitis B - Pipeline by Green Cross Corporation, H1 2016 86 Hepatitis B - Pipeline by HEC Pharm Co., Ltd., H1 2016 87 Hepatitis B - Pipeline by Humabs BioMed SA, H1 2016 88 Hepatitis B - Pipeline by Immunotope, Inc., H1 2016 89 Hepatitis B - Pipeline by Immunovaccine, Inc., H1 2016 90 Hepatitis B - Pipeline by Indian Immunologicals Limited, H1 2016 91 Hepatitis B - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 92 Hepatitis B - Pipeline by ISA Pharmaceuticals B.V., H1 2016 93 Hepatitis B - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2016 94 Hepatitis B - Pipeline by Johnson & Johnson, H1 2016 95 Hepatitis B - Pipeline by Kineta, Inc., H1 2016 96 Hepatitis B - Pipeline by Kuros Biosciences AG, H1 2016 97 Hepatitis B - Pipeline by Leukocare AG, H1 2016 98 Hepatitis B - Pipeline by LG Life Science LTD., H1 2016 99 Hepatitis B - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016 100 Hepatitis B - Pipeline by Mologen AG, H1 2016 101 Hepatitis B - Pipeline by Mucosis B.V., H1 2016 102 Hepatitis B - Pipeline by MultiCell Technologies, Inc., H1 2016 103 Hepatitis B - Pipeline by Panacea Biotec Limited, H1 2016 104 Hepatitis B - Pipeline by Pfenex Inc., H1 2016 105 Hepatitis B - Pipeline by PharmaEssentia Corporation, H1 2016 106 Hepatitis B - Pipeline by Profectus BioSciences, Inc., H1 2016 107 Hepatitis B - Pipeline by Redx Pharma Plc, H1 2016 108 Hepatitis B - Pipeline by REPLICor Inc., H1 2016 109 Hepatitis B - Pipeline by Sanofi Pasteur SA, H1 2016 110 Hepatitis B - Pipeline by SEEK Group, H1 2016 111 Hepatitis B - Pipeline by Sinovac Biotech Ltd., H1 2016 112 Hepatitis B - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016 113 Hepatitis B - Pipeline by Staidson (Beijing) Biopharmaceuticals Co., Ltd., H1 2016 114 Hepatitis B - Pipeline by TCM Biotech International Corp, H1 2016 115 Hepatitis B - Pipeline by TetraLogic Pharmaceuticals, H1 2016 116 Hepatitis B - Pipeline by TGV-Laboratories, H1 2016 117 Hepatitis B - Pipeline by Theravectys SA, H1 2016 118 Hepatitis B - Pipeline by Tomegavax, Inc., H1 2016 119 Hepatitis B - Pipeline by Transgene SA, H1 2016 120 Hepatitis B - Pipeline by UAB Profarma, H1 2016 121 Hepatitis B - Pipeline by Vaxine Pty Ltd, H1 2016 122 Hepatitis B - Pipeline by Viriom Ltd., H1 2016 123 Hepatitis B - Pipeline by VLP Biotech, Inc., H1 2016 124 Hepatitis B - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 125 Assessment by Monotherapy Products, H1 2016 126 Assessment by Combination Products, H1 2016 127 Number of Products by Stage and Target, H1 2016 129 Number of Products by Stage and Mechanism of Action, H1 2016 132 Number of Products by Stage and Route of Administration, H1 2016 135 Number of Products by Stage and Molecule Type, H1 2016 137 Hepatitis B Therapeutics - Recent Pipeline Updates, H1 2016 327 Hepatitis B - Dormant Projects, H1 2016 365 Hepatitis B - Dormant Projects (Contd..1), H1 2016 366 Hepatitis B - Dormant Projects (Contd..2), H1 2016 367 Hepatitis B - Dormant Projects (Contd..3), H1 2016 368 Hepatitis B - Dormant Projects (Contd..4), H1 2016 369 Hepatitis B - Dormant Projects (Contd..5), H1 2016 370 Hepatitis B - Dormant Projects (Contd..6), H1 2016 371 Hepatitis B - Dormant Projects (Contd..7), H1 2016 372 Hepatitis B - Dormant Projects (Contd..8), H1 2016 373 Hepatitis B - Dormant Projects (Contd..9), H1 2016 374 Hepatitis B - Discontinued Products, H1 2016 375


List of Figures
Number of Products under Development for Hepatitis B, H1 2016 26 Number of Products under Development for Hepatitis B - Comparative Analysis, H1 2016 27 Number of Products under Development by Companies, H1 2016 28 Number of Products under Investigation by Universities/Institutes, H1 2016 35 Comparative Analysis by Late Stage Development, H1 2016 36 Comparative Analysis by Clinical Stage Development, H1 2016 37 Comparative Analysis by Early Stage Products, H1 2016 38 Assessment by Monotherapy Products, H1 2016 126 Assessment by Combination Products, H1 2016 127 Number of Products by Top 10 Targets, H1 2016 128 Number of Products by Stage and Top 10 Targets, H1 2016 128 Number of Products by Top 10 Mechanism of Actions, H1 2016 131 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 131 Number of Products by Routes of Administration, H1 2016 134 Number of Products by Stage and Routes of Administration, H1 2016 134 Number of Products by Top 10 Molecule Types, H1 2016 136 Number of Products by Stage and Top 10 Molecule Types, H1 2016 136

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the marke

Read More...

Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is ant

Read More...

Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the dem

Read More...

Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to driv

Read More...

Global adhesives & sealants market size is expected to reach USD 43.19 billion by 2020, as per a new research report by Radiant Insights, Inc. Strong demand from packaging, construction and automotive industries is expected drive adhesives and sealan

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify